Olivier Paccoud

Dr. Olivier Paccoud


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
LGLaura Gouzien
Laura Gouzien
DCDidier Che
Didier Che
SCSophie Cassaing
Sophie Cassaing
OLOlivier Lortholary
Olivier Lortholary
VLValérie Letscher-Bru
Valérie Letscher-Bru
Fanny LanternierFanny Lanternier
Fanny Lanternier
Mucormycosis is a deadly invasive fungal infection recently included in the WHO priority pathogen list. Here we sought to describe epidemiological trends of mucormycosis in France, and to evaluate factors associated with mortality. From 2012 to 2022, we implemented a nationwide prospective surveillance programme for mucormycosis in France, focusing on epidemiology, species, seasonal variations. Factors associated with 3-month mortality were studied by univariable and multivariable logistic regression. Among 550 cases of mucormycosis, the main underlying conditions were haematological malignancy (HM, 65.1%, 358/550), trauma (8%, 44/550), diabetes (7.5%, 41/550) and solid-organ transplants (6.5%, 36/550). Site of infection was pulmonary in 52.4% (288/550), rhinocerebral in 14.5% (80/550), and cutaneo-articular in 17.1% (94/550). Main species identified were Rhizopus arrhizus (21%, 67/316), Rhizopus microsporus (13.6%, 43/316), Lichtheimia corymbifera and Mucor circinelloides (13.3%, 42/316 each), Rhizomucor pusillus (12%, 38/316), and Lichtheimia ramosa (10.8%, 34/316). We found associations between underlying condition, site of infection, and infecting species, including a previously undescribed triad of trauma, cutaneo-articular localisations, and L. ramosa/M. circinelloides. Diagnostic contribution of Polymerase Chain Reaction (PCR) increased from 16% (4/25) in 2012 to 91% (61/67) in 2022, with more than 50% of diagnoses relying solely on PCR in 2022. We also found seasonal variations with relatively more cases in autumn. Ninety-day mortality was 55.8% (276/495). Independent prognostic factors were age, diagnosis in Intensive Care Unit (ICU), and HM while diagnosis after 2015 (i.e. large implementation of PCR) and surgery were associated with reduced mortality. This study reveals major mucormycosis epidemiological changes in France, with a large predominance of HM patients, and a parallel between PCR multicentre implementation and improved prognosis. We also evidence new associations between species, localisations and risk factors, as well as seasonal variations. Recurrent financial support from Santé Publique France and 10.13039/501100003762 Institut Pasteur .

21 April 2021 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
OPOlivier Paccoud
Olivier Paccoud
NMNizar Mahlaoui
Nizar Mahlaoui
DMDespina Moshous
Despina Moshous
CAClaire Aguilar
Claire Aguilar
BNBénédicte Neven
Bénédicte Neven
TNThe Ceredih Network
The Ceredih Network

29 March 2024 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
OPOlivier Paccoud
Olivier Paccoud
MDMarie Desnos-Ollivier
Marie Desnos-Ollivier
FPFlorence Persat
Florence Persat
MDMagalie Demar
Magalie Demar
KBKarine Boukris-Sitbon
Karine Boukris-Sitbon
FGFrench Mycoses Study Group
French Mycoses Study Group

25 April 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OPOlivier Paccoud
Olivier Paccoud
NVNicolas Vignier
Nicolas Vignier
MBMohammed Boui
Mohammed Boui
MMMélanie Migaud
Mélanie Migaud
PVPierre Vironneau
Pierre Vironneau
Fanny LanternierFanny Lanternier
Fanny Lanternier
Phaeohyphomycoses comprise a heterogeneous group of fungal infections caused by dematiaceous fungi and have primarily been reported in patients with underlying acquired immunodeficiencies, such as hematological malignancies or solid-organ transplants. Over the past decade, a growing number of patients with phaeohyphomycosis but otherwise healthy were reported with autosomal recessive (AR) CARD9 deficiency. We report a 28-year-old woman who presented with invasive rhinosinusitis caused by Alternaria infectoria. Following a candidate gene sequencing approach, we identified a biallelic loss-of-function mutation of CARD9, thereby further broadening the spectrum of invasive fungal diseases found in patients with inherited CARD9 deficiency. In addition, we reviewed 17 other cases of phaeohyphomycosis associated with AR CARD9 deficiency. Physicians should maintain a high degree of suspicion for inborn errors of immunity, namely CARD9 deficiency, when caring for previously healthy patients with phaeohyphomycosis, regardless of age at first presentation.

16 March 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OPOlivier Paccoud
Olivier Paccoud
MBMarie-Elisabeth Bougnoux
Marie-Elisabeth Bougnoux
MDMarie Desnos-Ollivier
Marie Desnos-Ollivier
BVBruno Varet
Bruno Varet
Olivier LortholaryOlivier Lortholary
Olivier Lortholary
Fanny LanternierFanny Lanternier
Fanny Lanternier
Recent outbreaks of Cryptococcus gattii (CG) infections in North America have sparked renewed interest in the pathogenic potential of CG, and have underscored notable differences with Cryptococcus neoformans in terms of geographic distribution, pathogen virulence, and host susceptibility. While cases of CG are increasingly reported in patients with a wide variety of underlying conditions, only very few have been reported in patients with lymphoid neoplasms. Herein, we report a case of autochthonous CG meningitis in a patient receiving ibrutinib for chronic lymphocytic leukemia in France, and review available data on the clinical epidemiology of CG infections in patients with lymphoid neoplasms. We also summarise recent data on the host responses to CG infection, as well as the potential management pitfalls associated with its treatment in the haematological setting. The clinical epidemiology, clinical presentation, and course of disease during infections caused by CG involve complex interactions between environmental exposure to CG, infecting genotype, pathogen virulence factors, host susceptibility, and host immune responses. Future treatment guidelines should address the challenges associated with the management of antifungal treatments in the onco-haematological setting and the potential drug-drug interactions.

13 October 2024 in Transplant Infectious Disease
Verified
Journal Article
Closed access
LCLaurène Cachera
Laurène Cachera
EOErwan Oehler
Erwan Oehler
KAKarim Abdelmoumen
Karim Abdelmoumen
TLTARDIEU LAURENE
TARDIEU LAURENE
ITIan Thomas
Ian Thomas
LELoïc Epelboin
Loïc Epelboin